A novel ruthenium(II) arene based intercalator with potent anticancer activity.
The new ruthenium(II) compound [(eta6-p-cymene)Ru(N insertion mark C)Cl] (HN insertion mark C=9-aminoacridine (9-HAA)) shows a potent in vitro anticancer activity.
Ruiz
José
J
Departamento de Química Inorgánica, Facultad de Química, Universidad de Murcia, 30071, Murcia, Spain. jruiz@um.es
Vicente
Consuelo
C
de Haro
Concepción
C
Bautista
Delia
D
D000970:Antineoplastic Agents / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D018360:Crystallography, X-Ray; D000081007:Cymenes; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D020128:Inhibitory Concentration 50; D007364:Intercalating Agents / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D008958:Models, Molecular; D015394:Molecular Structure; D009942:Organometallic Compounds / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D012428:Ruthenium / Q000737:chemistry*
C543743:(eta6-p-cymene)Ru(9-aminoacridine)Cl; D000970:Antineoplastic Agents; D000081007:Cymenes; D007364:Intercalating Agents; D009942:Organometallic Compounds; D012428:Ruthenium